Macquarie Group
TXG icon

Macquarie Group’s 10x Genomics TXG Stock Holding History

Macquarie Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-76,524
Closed -$2.92M – 2144
2022
Q2 		$3.46M Sell
76,524
-55,293
-42% -$2.87M ﹤0.01% 1132
2022
Q1 		$11.9K Buy
131,817
+58,401
+80% +$5.11M 0.01% 896
2021
Q4 		$10.9M Sell
73,416
-505,524
-87% -$77.4M 0.01% 910
2021
Q3 		$84.3M Sell
578,940
-4,381
-0.8% -$752K 0.07% 348
2021
Q2 		$114M Buy
583,321
+105,609
+22% +$19.1M 0.09% 271
2021
Q1 		$86.5M Buy
+477,712
New +$82.5M 0.12% 190

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group's TXG Position: Q3 2022 in Review

Macquarie Group sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 76,524 shares — an estimated $2.92M sold.

Macquarie Group first reported a position in TXG in Q1 2021 and held it in 6 quarters. The position peaked at $114M in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

  • Macquarie Group reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 76,524 10x Genomics shares in Q3 2022, an estimated $2.92M.
  • Macquarie Group first reported a position in 10x Genomics in Q1 2021 and held it in 6 quarters.
  • Macquarie Group's 10x Genomics position peaked at $114M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.